Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode

References

1. 1.↵
   2. Choudhary S,
   3. Boldogh I,
   4. Brasier AR.

   Inside-out signaling pathways from nuclear reactive oxygen species control pulmonary innate immunity. J Innate Immun. 2016; 8: 143–55.

   OpenUrlCrossRef
2. 2.↵
   2. Crivellaro S,
   3. Panuzzo C,
   4. Carrà G,
   5. Volpengo A,
   6. Crasto F,
   7. Gottardi E, et al.

   Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion. Oncotarget. 2015; 6: 25217–25.

   OpenUrl
3. 3.↵
   2. Pazarentzos E,
   3. Mahul-Mellier AL,
   4. Datler C,
   5. Chaisaklert W,
   6. Hwang MS,
   7. Kroon J, et al.

   IκBα inhibits apoptosis at the outer mitochondrial membrane independently of NF-κB retention. EMBO J. 2014; 33: 2814–28.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   2. Cogswell PC,
   3. Kashatus DF,
   4. Keifer JA,
   5. Guttridge DC,
   6. Reuther JY,
   7. Bristow C, et al.

   NF-κB and IκBα are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-κB. J Biol Chem. 2003; 278: 2963–8.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Vlahopoulos SA,
   3. Cen O,
   4. Hengen N,
   5. Agan J,
   6. Moschovi M,
   7. Critselis E, et al.

   Dynamic aberrant NF-κB spurs tumorigenesis: A new model encompassing the microenvironment. Cytokine Growth Factor Rev. 2015; 26: 389–403.

   OpenUrlCrossRef
6. 6.
   2. Sepuri NBV,
   3. Tammineni P,
   4. Mohammed F,
   5. Paripati A.

   Nuclear transcription factors in the mitochondria: a new paradigm in fine-tuning mitochondrial metabolism. In: Handbook of Experimental Pharmacology. Berlin Heidelberg: Springer; 2016. doi: 10.1007/164-2016-3.

   OpenUrlCrossRef
7. 7.↵
   2. Schmidt SF,
   3. Larsen BD,
   4. Loft A,
   5. Nielsen R,
   6. Madsen JGS,
   7. Mandrup S.

   Acute TNF-induced repression of cell identity genes is mediated by NFκB-directed redistribution of cofactors from super-enhancers. Genome Res. 2015; 25: 1281–94.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Brown JD,
   3. Lin CY,
   4. Duan Q,
   5. Griffin G,
   6. Federation AJ,
   7. Paranal RM, et al.

   NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell. 2014; 56: 219–31.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.
   2. Kalita M,
   3. Tian B,
   4. Gao BN,
   5. Choudhary S,
   6. Wood TG,
   7. Carmical JR, et al.

   Systems approaches to modeling chronic mucosal inflammation. BioMed Res Int. 2013; 2013: 505864

   OpenUrl
10. 10.↵
    2. Park MH,
    3. Hong JT.

    Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells. 2016; 5: E15 doi: 10.3390/cells5020015.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Ba XQ,
    3. Aguilera-Aguirre L,
    4. Sur S,
    5. Boldogh I.

    8-oxoguanine DNA glycosylase-1-driven DNA base excision repair: role in asthma pathogenesis. Curr Opin Allergy Clin Immunol. 2015; 15: 89–97.

    OpenUrlCrossRefPubMed
12. 12.
    2. Brasier AR.

    The NF-κB regulatory network. Cardiovasc Toxicol. 2006; 6: 111–30.

    OpenUrlCrossRefPubMed
13. 13.
    2. May MJ

    2. Mihalas AB,
    3. Meffert MK.

    IKK kinase assay for assessment of canonical NF-κB activation in neurons. In: May MJ, editor. NF-kappa B: Methods and Protocols. New York: Springer. 2015; 61–74.
14. 14.↵
    2. Häcker H,
    3. Karin M.

    Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006; 2006: re13.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    2. Zhao YX,
    3. Tian B,
    4. Edeh CB,
    5. Brasier AR.

    Quantitation of the dynamic profiles of the innate immune response using multiplex selected reaction monitoring-mass spectrometry. Mol Cell Proteomics. 2013; 12: 1513–29.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    2. Vlahopoulos S,
    3. Boldogh I,
    4. Casola A,
    5. Brasier AR.

    Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation. Blood. 1999; 94: 1878–89.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    2. Cieślik M,
    3. Bekiranov S.

    Genome-wide predictors of NF-κB recruitment and transcriptional activity. BioData Mining. 2015; 8: 37

    OpenUrl
18. 18.↵
    2. Casola A,
    3. Garofalo RP,
    4. Jamaluddin M,
    5. Vlahopoulos S,
    6. Brasier AR.

    Requirement of a novel upstream response element in respiratory syncytial virus-induced IL-8 gene expression. J Immunol. 2000; 164: 5944–51.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    2. Brasier AR,
    3. Jamaluddin M,
    4. Casola A,
    5. Duan WL,
    6. Shen Q,
    7. Garofalo RP.

    A promoter recruitment mechanism for tumor necrosis factor-α-induced interleukin-8 transcription in type II pulmonary epithelial cells. Dependence on nuclear abundance of Rel A, NF-κB1, and c-Rel transcription factors. J Biol Chem. 1998; 273: 3551–61.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    2. Aguilera-Aguirre L,
    3. Bacsi A,
    4. Radak Z,
    5. Hazra TK,
    6. Mitra S,
    7. Sur S, et al.

    Innate inflammation induced by the 8-oxoguanine DNA glycosylase-1-KRAS-NF-κB pathway. J Immunol. 2014; 193: 4643–53.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    2. Zhao WN,
    3. Breese E,
    4. Bowers A,
    5. Hoggatt J,
    6. Pelus LM,
    7. Broxmeyer HE, et al.

    SIMPL enhancement of tumor necrosis factor-α dependent p65-MED1 complex formation is required for mammalian hematopoietic stem and progenitor cell function. PLoS One. 2013; 8: e61123
22. 22.↵
    2. Tian B,
    3. Nowak DE,
    4. Jamaluddin M,
    5. Wang SF,
    6. Brasier AR.

    Identification of direct genomic targets downstream of the nuclear factor-κB transcription factor mediating tumor necrosis factor signaling. J Biol Chem. 2005; 280: 17435–48.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    2. Jamaluddin M,
    3. Wang SF,
    4. Boldogh I,
    5. Tian B,
    6. Brasier AR.

    TNF-α-induced NF-κB/RelA Ser276 phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal. 2007; 19: 1419–33.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    2. Moschovi M,
    3. Critselis E,
    4. Cen O,
    5. Adamaki M,
    6. Lambrou GI,
    7. Chrousos GP, et al.

    Drugs acting on homeostasis: challenging cancer cell adaptation. Expert Rev Anticancer Ther. 2015; 15: 1405–17.

    OpenUrl
25. 25.↵
    2. Song C,
    3. Mitter SK,
    4. Qi X,
    5. Beli E,
    6. Rao HV,
    7. Ding J, et al.

    Oxidative stress-mediated NFκB phosphorylation upregulates p62/SQSTM1 and promotes retinal pigmented epithelial cell survival through increased autophagy. PLoS One. 2017; 12: e0171940
26. 26.↵
    2. Shaaban S,
    3. Negm A,
    4. Ibrahim EE,
    5. Elrazak AA.

    Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncol Rev. 2014; 8: 246

    OpenUrl
27. 27.↵
    2. Sun BH,
    3. Shah B,
    4. Fiskus W,
    5. Qi J,
    6. Rajapakshe K,
    7. Coarfa C, et al.

    Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015; 126: 1565–74.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    2. Zhang BG,
    3. Hu L,
    4. Zang MD,
    5. Wang HX,
    6. Zhao W,
    7. Li JF, et al.

    Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFκB pathway in gastric cancer development. Oncotarget. 2016; 7: 9788–800.

    OpenUrl
29. 29.↵
    2. Hu GK,
    3. Gong AY,
    4. Wang Y,
    5. Ma SB,
    6. Chen XQ,
    7. Chen J, et al.

    LincRNA-Cox2 promotes late inflammatory gene transcription in macrophages through modulating SWI/SNF-mediated chromatin remodeling. J Immunol. 2016; 196: 2799–808.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    2. Jones VS,
    3. Huang RY,
    4. Chen LP,
    5. Chen ZS,
    6. Fu LW,
    7. Huang RP.

    Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochim Biophys Acta. 2016; 1865: 255–65.

    OpenUrlPubMed
31. 31.↵
    2. Renema N,
    3. Navet B,
    4. Heymann MF,
    5. Lezot F,
    6. Heymann D.

    RANK-RANKL signalling in cancer. Biosci Rep. 2016; 36: e00366 doi: 10.1042/BSR20160150.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    2. Dmitrieva OS,
    3. Shilovskiy IP,
    4. Khaitov MR,
    5. Grivennikov SI.

    Interleukins 1 and 6 as Main Mediators of Inflammation and Cancer. Biochem Biokhimiia. 2016; 81: 80–90.

    OpenUrl
33. 33.↵
    2. Klein JC,
    3. Moses K,
    4. Zelinskyy G,
    5. Sody S,
    6. Buer J,
    7. Lang S, et al.

    Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun. 2017; 8: 14600

    OpenUrl
34. 34.↵
    2. Park H,
    3. Kim SH,
    4. Cho YM,
    5. Ihm HJ,
    6. Oh YS,
    7. Hong SH, et al.

    Increased expression of nuclear factor kappa-B p65 subunit in adenomyosis. Obstet Gynecol Sci. 2016; 59: 123–9.

    OpenUrl
35. 35.↵
    2. Haricharan S,
    3. Li Y.

    STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. Mol Cell Endocrinol. 2014; 382: 560–9.

    OpenUrlCrossRefPubMed
36. 36.
    2. Park MH,
    3. Hong JE,
    4. Hwang CJ,
    5. Choi M,
    6. Choi JS,
    7. An YJ, et al.

    Synergistic inhibitory effect of cetuximab and tectochrysin on human colon cancer cell growth via inhibition of EGFR signal. Arch Pharm Res. 2016; 39: 721–9.

    OpenUrl
37. 37.↵
    2. Yun HM,
    3. Park MH,
    4. Kim DH,
    5. Ahn YJ,
    6. Park KR,
    7. Kim TM, et al.

    Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development. Oncogene. 2014; 33: 5193–200.

    OpenUrlCrossRef
38. 38.↵
    2. Qiao YC,
    3. He H,
    4. Jonsson P,
    5. Sinha I,
    6. Zhao CY,
    7. Dahlman-Wright K.

    AP-1 is a key regulator of proinflammatory cytokine TNFα- mediated triple-negative breast cancer progression. J Biol Chem. 2016; 291: 5068–79.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    2. Vlahopoulos SA,
    3. Logotheti S,
    4. Mikas D,
    5. Giarika A,
    6. Gorgoulis V,
    7. Zoumpourlis V.

    The role of ATF-2 in oncogenesis. BioEssays. 2008; 30: 314–27.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    2. Bhoumik A,
    3. Takahashi S,
    4. Breitweiser W,
    5. Shiloh Y,
    6. Jones N,
    7. Ronai Z.

    ATM-dependent phosphorylation of ATF2 is required for the DNA damage response. Mol Cell. 2005; 18: 577–87.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    2. Vlahopoulos S,
    3. Zoumpourlis VC.

    JNK: a key modulator of intracellular signaling. Biochemistry. 2004; 69: 844–54.

    OpenUrlPubMed
42. 42.↵
    2. Park WY,
    3. Hong BJ,
    4. Lee J,
    5. Choi C,
    6. Kim MY.

    H3K27 demethylase JMJD3 employs the NF-κB and BMP signaling pathways to modulate the tumor microenvironment and promote melanoma progression and metastasis. Cancer Res. 2016; 76: 161–70.

    OpenUrlAbstract/FREE Full Text
43. 43.↵
    2. Vasseur R,
    3. Skrypek N,
    4. Duchêne B,
    5. Renaud F,
    6. Martínez-Maqueda D,
    7. Vincent A, et al.

    The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways. Biochim Biophys Acta. 2015; 1849: 1375–84.

    OpenUrl
44. 44.↵
    2. Yun HM,
    3. Jin P,
    4. Park KR,
    5. Hwang J,
    6. Jeong HS,
    7. Kim EC, et al.

    Thiacremonone potentiates anti-oxidant effects to improve memory dysfunction in an APP/PS1 transgenic mice model. Mol Neurobiol. 2016; 53: 2409–20.

    OpenUrl
45. 45.↵
    2. Thompson RC,
    3. Vardinogiannis I,
    4. Gilmore TD.

    The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One. 2013; 8: e62822
46. 46.↵
    2. Lee NJ,
    3. Choi DY,
    4. Song JK,
    5. Jung YY,
    6. Kim DH,
    7. Kim TM, et al.

    Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model. Carcinogenesis. 2012; 33: 2520–8.

    OpenUrlCrossRefPubMed
47. 47.↵
    2. Fernandez MV,
    3. Miller E,
    4. Krammer F,
    5. Gopal R,
    6. Greenbaum BD,
    7. Bhardwaj N.

    Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells. J Leukoc Biol. 2016; 99: 723–34.

    OpenUrlCrossRefPubMed
48. 48.
    2. Hosakote YM,
    3. Brasier AR,
    4. Casola A,
    5. Garofalo RP,
    6. Kurosky A.

    Respiratory Syncytial Virus infection triggers epithelial HMGB1 release as a damage-associated molecular pattern promoting a monocytic inflammatory response. J Virol. 2016; 90: 9618–31. doi: 10.1128/JVI.01279-16.

    OpenUrlAbstract/FREE Full Text
49. 49.
    2. Kolli D,
    3. Gupta MR,
    4. Sbrana E,
    5. Velayutham TS,
    6. Chao H,
    7. Casola A, et al.

    Alveolar macrophages contribute to the pathogenesis of human metapneumovirus infection while protecting against respiratory syncytial virus infection. Am J Respir Cell Mol Biol. 2014; 51: 502–15.

    OpenUrlCrossRefPubMed
50. 50.
    2. Mastellos DC,
    3. DeAngelis RA,
    4. Lambris JD.

    Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Semin Immunol. 2013; 25: 29–38.

    OpenUrlCrossRefPubMed
51. 51.↵
    2. Bai L,
    3. Chen W,
    4. Chen JT,
    5. Li W,
    6. Zhou L,
    7. Niu C, et al.

    Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application. J Transl Med. 2017; 15: 51

    OpenUrl
52. 52.↵
    2. Chen BJ,
    3. Frangogiannis NG.

    Immune cells in repair of the infarcted myocardium. Microcirculation. 2016; 24 doi: 10.1111/micc.l2305.

    OpenUrlCrossRef
53. 53.↵
    2. Jamaluddin M,
    3. Choudhary S,
    4. Wang SF,
    5. Casola A,
    6. Huda R,
    7. Garofalo RP, et al.

    Respiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-κB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoter. J Virol. 2005; 79: 15302–13.

    OpenUrlAbstract/FREE Full Text
54. 54.↵
    2. Ray S,
    3. Zhao YX,
    4. Jamaluddin M,
    5. Edeh CB,
    6. Lee C,
    7. Brasier AR.

    Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis. Cell Signal. 2014; 26: 1445–55.

    OpenUrlCrossRefPubMed
55. 55.↵
    2. Bao XY,
    3. Indukuri H,
    4. Liu TS,
    5. Liao SL,
    6. Tian B,
    7. Brasier AR, et al.

    IKKε modulates RSV-induced NF-κB-dependent gene transcription. Virology. 2010; 408: 224–31.

    OpenUrlCrossRefPubMed
56. 56.↵
    2. Chamoux E,
    3. McManus S,
    4. Laberge G,
    5. Bisson M,
    6. Roux S.

    Involvement of kinase PKC-zeta in the p62/p62(P392L)-driven activation of NF-κB in human osteoclasts. Biochim Biophys Acta. 2013; 1832: 475–84.

    OpenUrlCrossRef
57. 57.↵
    2. Ren J,
    3. Wang QW,
    4. Morgan S,
    5. Si Y,
    6. Ravichander A,
    7. Dou CL, et al.

    Protein kinase C-δ (PKCδ) regulates proinflammatory chemokine expression through cytosolic interaction with the NF-κB subunit p65 in vascular smooth muscle cells. J Biol Chem. 2014; 289: 9013–26.

    OpenUrlAbstract/FREE Full Text
58. 58.↵
    2. Pan L,
    3. Zhu B,
    4. Hao WJ,
    5. Zeng XL,
    6. Vlahopoulos SA,
    7. Hazra TK, et al.

    Oxidized guanine base lesions function in 8-oxoguanine DNA glycosylase1-mediated epigenetic regulation of nuclear factor κB-driven gene expression. J Biol Chem. 2016; 291: 25553–6. doi: 10.1074/jbc.M116.751453.

    OpenUrlAbstract/FREE Full Text
59. 59.↵
    2. Mina M,
    3. Magi S,
    4. Jurman G,
    5. Itoh M,
    6. Kawaji H,
    7. Lassmann T, et al.

    Promoter-level expression clustering identifies time development of transcriptional regulatory cascades initiated by ErbB receptors in breast cancer cells. Sci Rep. 2015; 5: 11999

    OpenUrlCrossRefPubMed
60. 60.↵
    2. Yaniv M.

    Chromatin remodeling: from transcription to cancer. Cancer Genet. 2014; 207: 352–7.

    OpenUrlCrossRefPubMed
61. 61.↵
    2. Zouein FA,
    3. Altara R,
    4. Chen Q,
    5. Lesnefsky EJ,
    6. Kurdi M,
    7. Booz GW.

    Pivotal importance of STAT3 in protecting the heart from acute and chronic stress: new advancement and unresolved issues. Front Cardiovasc Med. 2015; 2: 36

    OpenUrl
62. 62.↵
    2. Kamitani S,
    3. Togi S,
    4. Ikeda O,
    5. Nakasuji M,
    6. Sakauchi A,
    7. Sekine Y, et al.

    Krüppel-associated box-associated protein 1 negatively regulates TNF-α-induced NF-κB transcriptional activity by influencing the interactions among STAT3, p300, and NF-κB/p65. J Immunol. 2011; 187: 2476–83.

    OpenUrlAbstract/FREE Full Text
63. 63.↵
    2. Witte S,
    3. Bradley A,
    4. Enright AJ,
    5. Muljo SA.

    High-density P300 enhancers control cell state transitions. BMC Genomics. 2015; 16: 903

    OpenUrl
64. 64.↵
    2. Gharavi NM,
    3. Alva JA,
    4. Mouillesseaux KP,
    5. Lai C,
    6. Yeh M,
    7. Yeung W, et al.

    Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem. 2007; 282: 31460–8.

    OpenUrlAbstract/FREE Full Text
65. 65.↵
    2. Sakelliou A,
    3. Fatouros IG,
    4. Athanailidis I,
    5. Tsoukas D,
    6. Chatzinikolaou A,
    7. Draganidis D, et al.

    Evidence of a redox-dependent regulation of immune responses to exercise-induced inflammation. Oxid Med Cell Longev. 2016; 2016: 2840643

    OpenUrl
66. 66.↵
    2. Yang JB,
    3. Liao XD,
    4. Agarwal MK,
    5. Barnes L,
    6. Auron PE,
    7. Stark GR.

    Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev. 2007; 21: 1396–408.
67. 67.↵
    2. Dong L,
    3. Stevens JL,
    4. Jaken S.

    Transformation-sensitive localization of alpha-protein kinase C at cell-cell contacts in rat renal proximal tubule epithelial cells. Cell Growth Differ. 1993; 4: 793–8.

    OpenUrlAbstract
68. 68.↵
    2. Li J,
    3. Vesey DA,
    4. Johnson DW,
    5. Gobe GC.

    Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther. 2007; 6: 1944–50.

    OpenUrlCrossRefPubMedWeb of Science
69. 69.↵
    2. Yoshida Y,
    3. Kumar A,
    4. Koyama Y,
    5. Peng HB,
    6. Arman A,
    7. Boch JA, et al.

    Interleukin 1 activates STAT3/nuclear factor-κB cross-talk via a unique TRAF6- and p65-dependent mechanism. J Biol Chem. 2004; 279: 1768–76.

    OpenUrlAbstract/FREE Full Text
70. 70.↵
    2. Kim SJ,
    3. Yoon S.

    Activated Rac1 regulates the degradation of IκBα and the nuclear translocation of STAT3-NFκB complexes in starved cancer cells. Exp Mol Med. 2016; 48: e231
71. 71.↵
    2. Doucas V,
    3. Shi Y,
    4. Miyamoto S,
    5. West A,
    6. Verma I,
    7. Evans RM.

    Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA. 2000; 97: 11893–8.

    OpenUrlAbstract/FREE Full Text
72. 72.↵
    2. Lee H,
    3. Herrmann A,
    4. Deng JH,
    5. Kujawski M,
    6. Niu GL,
    7. Li ZW, et al.

    Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell. 2009; 15: 283–93.

    OpenUrlCrossRefPubMedWeb of Science
73. 73.↵
    2. Xu YS,
    3. Liang JJ,
    4. Wang YM,
    5. Zhao XZJ,
    6. Xu L,
    7. Xu YY, et al.

    STAT3 undergoes acetylation-dependent mitochondrial translocation to regulate pyruvate metabolism. Sci Rep. 2016; 6: 39517

    OpenUrl
74. 74.↵
    2. Walker EC,
    3. Johnson RW,
    4. Hu YF,
    5. Brennan HJ,
    6. Poulton IJ,
    7. Zhang J-G, et al.

    Murine oncostatin m acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an Effect that protects bone mass. J Biol Chem. 2016; 291: 21703–16.

    OpenUrlAbstract/FREE Full Text
75. 75.↵
    2. Chatterjee B,
    3. Banoth B,
    4. Mukherjee T,
    5. Taye N,
    6. Vijayaragavan B,
    7. Chattopadhyay S, et al.

    Late-phase synthesis of IκBα insulates the TLR4-activated canonical NF-κB pathway from noncanonical NF-κB signaling in macrophages. Sci Signal. 2016; 9: ra120

    OpenUrlAbstract/FREE Full Text
76. 76.↵
    2. Rocha S,
    3. Garrett MD,
    4. Campbell KJ,
    5. Schumm K,
    6. Perkins ND.

    Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 2005; 24: 1157–69.

    OpenUrlAbstract/FREE Full Text
77. 77.↵
    2. Christian F,
    3. Smith EL,
    4. Carmody RJ.

    The regulation of NF-κB subunits by phosphorylation. Cells. 2016; 5: 12 doi: 10.3390/cells5010012.

    OpenUrlCrossRefPubMed
78. 78.↵
    2. Moles A,
    3. Butterworth JA,
    4. Sanchez A,
    5. Hunter JE,
    6. Leslie J,
    7. Sellier H, et al.

    A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-κB-dependent liver regeneration and cancer. Oncogene. 2016; 35: 4623–32.

    OpenUrl
79. 79.↵
    2. Mangoni M,
    3. Sottili M,
    4. Gerini C,
    5. Desideri I,
    6. Bastida C,
    7. Pallotta S, et al.

    A PPAR-gamma agonist protects from radiation-induced intestinal toxicity. United Eur Gastroenterol J. 2017; 5: 218–26.

    OpenUrl
80. 80.↵
    2. Hwang JW,
    3. Cho H,
    4. Lee JY,
    5. Jeon Y,
    6. Kim SN,
    7. Lee SJ, et al.

    The synthetic ajoene analog SPA3015 induces apoptotic cell death through crosstalk between NF-κΒ and PPARγ in multidrug-resistant cancer cells. Food Chem Toxicol. 2016; 96: 35–42.

    OpenUrlPubMed
81. 81.↵
    2. Pazienza V,
    3. Vinciguerra M,
    4. Mazzoccoli G.

    PPARs signaling and cancer in the gastrointestinal system. PPAR Res. 2012; 2012: 560846

    OpenUrlPubMed
82. 82.↵
    2. Pozzi A,
    3. Capdevila JH.

    PPARα ligands as antitumorigenic and antiangiogenic agents. PPAR Res. 2008; 2008: 906542

    OpenUrlPubMed
83. 83.↵
    2. Narayanan KB,
    3. Ali M,
    4. Barclay BJ,
    5. Cheng Q,
    6. D'Abronzo L,
    7. Dornetshuber-Fleiss R, et al.

    Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Carcinogenesis. 2015; 36(Suppl 1): S89–110. doi: 10.1093/carcin/bgv032.

    OpenUrlCrossRefPubMed
84. 84.↵
    2. Fecher RA,
    3. Horwath MC,
    4. Friedrich D,
    5. Rupp J,
    6. Deepe GS Jr..

    Inverse correlation between IL-10 and HIF-1α in macrophages infected with Histoplasma capsulatum. J Immunol. 2016; 197: 565–79.

    OpenUrlAbstract/FREE Full Text
85. 85.↵
    2. Ben-Shoshan J,
    3. Maysel-Auslender S,
    4. Mor A,
    5. Keren G,
    6. George J.

    Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1α. Eur J Immunol. 2008; 38: 2412–8.

    OpenUrlCrossRefPubMedWeb of Science
86. 86.↵
    2. Cheng ZX,
    3. Wang DW,
    4. Liu T,
    5. Liu WX,
    6. Xia WB,
    7. Xu J, et al.

    Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells. Oncol Rep. 2014; 31: 1891–8.

    OpenUrlPubMed
87. 87.↵
    2. Chen JC,
    3. Huang AJ,
    4. Chen SC,
    5. Wu JL,
    6. Wu WM,
    7. Chiang HS, et al.

    Interleukin-27 and interleukin-12 augment activation of distinct cord blood natural killer cells responses via STAT3 pathways. J Formos Med Assoc. 2012; 111: 275–83.

    OpenUrlPubMed
88. 88.↵
    2. Ma XJ,
    3. Yan WJ,
    4. Zheng H,
    5. Du QL,
    6. Zhang LX,
    7. Ban Y, et al.

    Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells. F1000Res. 2015; 4: F1000 doi: 10.12688/f1000research.7010.1.

    OpenUrlCrossRef
89. 89.↵
    2. Larousserie F,
    3. Charlot P,
    4. Bardel E,
    5. Froger J,
    6. Kastelein RA,
    7. Devergne O.

    Differential effects of IL-27 on human B cell subsets. J Immunol. 2006; 176: 5890–7.

    OpenUrlAbstract/FREE Full Text
90. 90.
    2. El-behi M,
    3. Ciric B,
    4. Yu S,
    5. Zhang GX,
    6. Fitzgerald DC,
    7. Rostami A.

    Differential effect of IL-27 on developing versus committed Th17 cells. J Immunol. 2009; 183: 4957–67.

    OpenUrlAbstract/FREE Full Text
91. 91.↵
    2. Xu J,
    3. Yang Y,
    4. Qiu G,
    5. Lal G,
    6. Wu Z,
    7. Levy DE, et al.

    c-Maf regulates IL-10 expression during Th17 polarization. J Immunol. 2009; 182: 6226–36.

    OpenUrlAbstract/FREE Full Text
92. 92.↵
    2. Prasongsukarn K,
    3. Chaisri U,
    4. Chartburus P,
    5. Wetchabut K,
    6. Benjathummarak S,
    7. Khachansaksumet V, et al.

    Phenotypic alterations in human saphenous vein culture induced by tumor necrosis factor-alpha and lipoproteins: a preliminary development of an initial atherosclerotic plaque model. Lipids Health Dis. 2013; 12: 132

    OpenUrl
93. 93.
    2. Barone F,
    3. Gardner DH,
    4. Nayar S,
    5. Steinthal N,
    6. Buckley CD,
    7. Luther SA.

    Stromal fibroblasts in tertiary lymphoid structures: a novel target in chronic inflammation. Front Immunol. 2016; 7: 477

    OpenUrlPubMed
94. 94.
    2. Milićević NM,
    3. Nohroudi K,
    4. Schmidt F,
    5. Schmidt H,
    6. Ringer C,
    7. Sorensen GL, et al.

    Growth of murine splenic tissue is suppressed by lymphotoxin β-receptor signaling (LTβR) originating from splenic and non-splenic tissues. PLoS One. 2016; 11: e0166901
95. 95.↵
    2. Visciano C,
    3. Liotti F,
    4. Prevete N,
    5. Cali' G,
    6. Franco R,
    7. Collina F, et al.

    Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene. 2015; 34: 5175–86.

    OpenUrl
96. 96.↵
    2. Francescone R,
    3. Hou V,
    4. Grivennikov SI.

    Microbiome, inflammation and cancer. Cancer J. 2014; 20: 181–9.

    OpenUrlCrossRefPubMed
97. 97.↵
    2. Vendramini-Costa DB,
    3. Francescone R,
    4. Posocco D,
    5. Hou V,
    6. Dmitrieva O,
    7. Hensley H, et al.

    Anti-inflammatory natural product goniothalamin reduces colitis-associated and sporadic colorectal tumorigenesis. Carcinogenesis. 2017; 38: 51–63.

    OpenUrlCrossRefPubMed
98. 98.↵
    2. Ma Y,
    3. Galluzzi L,
    4. Zitvogel L,
    5. Kroemer G.

    Autophagy and cellular immune responses. Immunity. 2013; 39: 211–27.

    OpenUrlCrossRefPubMed
99. 99.↵
    2. Braun T,
    3. Carvalho G,
    4. Fabre C,
    5. Grosjean J,
    6. Fenaux P,
    7. Kroemer G.

    Targeting NF-κB in hematologic malignancies. Cell Death Differ. 2006; 13: 748–58.

    OpenUrlCrossRefPubMedWeb of Science
100. 100.↵
     2. Cilloni D,
     3. Martinelli G,
     4. Messa F,
     5. Baccarani M,
     6. Saglio G.

     Nuclear factor κB as a target for new drug development in myeloid malignancies. Haematologica. 2007; 92: 1224–9.

     OpenUrlAbstract/FREE Full Text
101. 101.↵
     2. Pérez L,
     3. Muñoz-Durango N,
     4. Riedel CA,
     5. Echeverría C,
     6. Kalergis AM,
     7. Cabello-Verrugio C, et al.

     Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine Growth Factor Rev. 2017; 33: 41–54.

     OpenUrl
102. 102.↵
     2. Copland JA,
     3. Sheffield-Moore M,
     4. Koldzic-Zivanovic N,
     5. Gentry S,
     6. Lamprou G,
     7. Tzortzatou-Stathopoulou F, et al.

     Sex steroid receptors in skeletal differentiation and epithelial neoplasia: is tissue-specific intervention possible? BioEssays. 2009; 31: 629–41.

     OpenUrlPubMed
103. 103.↵
     2. Diefenbacher ME,
     3. Litfin M,
     4. Herrlich P,
     5. Kassel O.

     The nuclear isoform of the LIM domain protein Trip6 integrates activating and repressing signals at the promoter-bound glucocorticoid receptor. Mol Cell Endocrinol. 2010; 320: 58–66.

     OpenUrlPubMed
104. 104.↵
     2. Chodankar R,
     3. Wu DY,
     4. Gerke DS,
     5. Stallcup MR.

     Selective coregulator function and restriction of steroid receptor chromatin occupancy by Hic-5. Mol Endocrinol. 2015; 29: 716–29.

     OpenUrl
105. 105.↵
     2. Bonomo A,
     3. Monteiro AC,
     4. Gonçalves-Silva T,
     5. Cordeiro-Spinetti E,
     6. Galvani RG,
     7. Balduino A.

     A T cell view of the bone marrow. Front Immunol. 2016; 7: 184

     OpenUrl
106. 106.↵
     2. Kortylewski M,
     3. Xin H,
     4. Kujawski M,
     5. Lee H,
     6. Liu Y,
     7. Harris T, et al.

     Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009; 15: 114–23.

     OpenUrlCrossRefPubMedWeb of Science
107. 107.↵
     2. Kong HY,
     3. Zhang QW,
     4. Zeng YH,
     5. Wang H,
     6. Wu MQ,
     7. Zheng TY, et al.

     Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures. Int J Clin Exp Med. 2015; 8: 8525–39.

     OpenUrl
108. 108.↵
     2. Lippitz BE,
     3. Harris RA.

     Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016; 5: e1093722
109. 109.↵
     2. Chen J,
     3. Li GS,
     4. Meng H,
     5. Fan YC,
     6. Song YH,
     7. Wang SR, et al.

     Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol. 2012; 61: 101–8.

     OpenUrl
110. 110.↵
     2. Shostak K,
     3. Zhang X,
     4. Hubert P,
     5. Göktuna SI,
     6. Jiang ZS,
     7. Klevernic I, et al.

     NF-κB-induced KIAA1199 promotes survival through EGFR signalling. Nat Commun. 2014; 5: 5232

     OpenUrlCrossRefPubMed
111. 111.
     2. Chou CH,
     3. Cheng YF,
     4. Siow TY,
     5. Kumar A,
     6. Peck K,
     7. Chang C.

     SCUBE3 regulation of early lung cancer angiogenesis and metastatic progression. Clin Exp Metastasis. 2013; 30: 741–52.

     OpenUrlCrossRef
112. 112.↵
     2. Lin KL,
     3. Cheng JN,
     4. Yang T,
     5. Li YS,
     6. Zhu B.

     EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. Biochem Biophys Res Commun. 2015; 463: 95–101.

     OpenUrl
113. 113.↵
     2. Arlauckas SP,
     3. Garris CS,
     4. Kohler RH,
     5. Kitaoka M,
     6. Cuccarese MF,
     7. Yang KS, et al.

     In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017; 9: eaal3604
114. 114.↵
     2. Geginat J,
     3. Larghi P,
     4. Paroni M,
     5. Nizzoli G,
     6. Penatti A,
     7. Pagani M, et al.

     The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. Cytokine Growth Factor Rev. 2016; 30: 87–93.

     OpenUrlPubMed
115. 115.↵
     2. Keating R,
     3. McGargill MA.

     mTOR regulation of lymphoid cells in immunity to pathogens. Front Immunol. 2016; 7: 180

     OpenUrlCrossRef
116. 116.↵
     2. Moschovi M,
     3. Adamaki M,
     4. Vlahopoulos SA.

     Progress in treatment of viral infections in children with acute lymphoblastic leukemia. Oncol Rev. 2016; 10: 300

     OpenUrl
117. 117.↵
     2. Montecalvo A,
     3. Watkins SC,
     4. Orange J,
     5. Kane LP.

     Inducible turnover of optineurin regulates T cell activation. Mol Immunol. 2017; 85: 9–17.

     OpenUrl
118. 118.↵
     2. Kuwahara I,
     3. Lillehoj EP,
     4. Koga T,
     5. Isohama Y,
     6. Miyata T,
     7. Kim KC.

     The signaling pathway involved in neutrophil elastase stimulated MUC1 transcription. Am J Respir Cell Mol Biol. 2007; 37: 691–8.

     OpenUrlCrossRefPubMedWeb of Science
119. 119.↵
     2. Jang JE,
     3. Eom JI,
     4. Jeung HK,
     5. Cheong JW,
     6. Lee JY,
     7. Kim JS, et al.

     Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells. Autophagy. 2017; 13: 761–2. doi: 10.1080/15548627.2016.1278328.

     OpenUrlCrossRef
120. 120.↵
     2. Chandrika G,
     3. Natesh K,
     4. Ranade D,
     5. Chugh A,
     6. Shastry P.

     Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling. Sci Rep. 2016; 6: 22455

     OpenUrl
121. 121.↵
     2. Grafone T,
     3. Palmisano M,
     4. Nicci C,
     5. Storti S.

     An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012; 6: e8
122. 122.↵
     2. Gross SM,
     3. Rotwein P.

     Mapping growth-factor-modulated Akt signaling dynamics. J Cell Sci. 2016; 129: 2052–63.

     OpenUrlAbstract/FREE Full Text
123. 123.↵
     2. Li S,
     3. Pinard M,
     4. Wang YL,
     5. Yang L,
     6. Lin RT,
     7. Hiscott J, et al.

     Crosstalk between the TNF and IGF pathways enhances NF-κB activation and signaling in cancer cells. Growth Horm IGF Res. 2015; 25: 253–61.

     OpenUrl
124. 124.
     2. Baik IH,
     3. Jo GH,
     4. Seo D,
     5. Ko MJ,
     6. Cho CH,
     7. Lee MG, et al.

     Knockdown of RPL9 expression inhibits colorectal carcinoma growth via the inactivation of Id-1/NF-κB signaling axis. Int J Oncol. 2016; 49: 1953–62.

     OpenUrlCrossRef
125. 125.↵
     2. Gu X,
     3. Hua ZY,
     4. Dong YD,
     5. Zhan Y,
     6. Zhang XW,
     7. Tian W, et al.

     Proteome and acetylome analysis identifies novel pathways and targets regulated by perifosine in Neuroblastoma. Sci Rep. 2017; 7: 42062

     OpenUrl
126. 126.↵
     2. Guan ZF,
     3. Li C,
     4. Fan JH,
     5. He DL,
     6. Li L.

     Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT→NF-kB→CXCL5 signaling. Sci Rep. 2016; 6: 37085

     OpenUrl
127. 127.↵
     2. Lin YW,
     3. Lee LM,
     4. Lee WJ,
     5. Chu CY,
     6. Tan P,
     7. Yang YC, et al.

     Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity. J Pineal Res. 2016; 60: 277–90.

     OpenUrlCrossRefPubMed
128. 128.↵
     2. Hu L,
     3. Shi Y,
     4. Hsu JH,
     5. Gera J,
     6. Van Ness B,
     7. Lichtenstein A.

     Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003; 101: 3126–35.

     OpenUrlAbstract/FREE Full Text
129. 129.↵
     2. Fiskus W,
     3. Sharma S,
     4. Qi J,
     5. Shah B,
     6. Devaraj SGT,
     7. Leveque C, et al.

     BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014; 13: 2315–27.

     OpenUrlAbstract/FREE Full Text
130. 130.↵
     2. Zhu B,
     3. Zhang JB,
     4. Chen J,
     5. Li CL,
     6. Wang XD.

     Molecular biological characteristics of the recruitment of hematopoietic stem cells from bone marrow niche in chronic myeloid leukemia. Int J Clin Exp Pathol. 2015; 8: 12595–607.

     OpenUrl
131. 131.
     2. Safaee M,
     3. Ivan ME,
     4. Oh MC,
     5. Oh T,
     6. Sayegh ET,
     7. Kaur G, et al.

     The role of epidermal growth factor-like module containing mucin-like hormone receptor 2 in human cancers. Oncol Rev. 2014; 8: 242

     OpenUrl
132. 132.↵
     2. Bresalier RS,
     3. Ho SB,
     4. Schoeppner HL,
     5. Kim YS,
     6. Sleisenger MH,
     7. Brodt P, et al.

     Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology. 1996; 110: 1354–67.

     OpenUrlCrossRefPubMedWeb of Science
133. 133.↵
     2. Zhu GF,
     3. Huang Y,
     4. Wu CT,
     5. Wei D,
     6. Shi YX.

     Activation of G-protein-coupled estrogen receptor inhibits the migration of human nonsmall cell lung cancer cells via IKK-β/NF-κB signals. DNA Cell Biol. 2016; 35: 434–42.

     OpenUrlCrossRefPubMed
134. 134.
     2. Lee CJ,
     3. Lee MH,
     4. Yoo SM,
     5. Choi KI,
     6. Song JH,
     7. Jang JH, et al.

     Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway. BMC Cancer. 2015; 15: 576

     OpenUrlPubMed
135. 135.↵
     2. Guarneri C,
     3. Bevelacqua V,
     4. Polesel J,
     5. Falzone L,
     6. Cannavò PS,
     7. Spandidos DA, et al.

     NF κB inhibition is associated with OPN/MMP 9 downregulation in cutaneous melanoma. Oncol Rep. 2017; 37: 737–46.

     OpenUrl
136. 136.↵
     2. Szebeni GJ,
     3. Vizler C,
     4. Kitajka K,
     5. Puskas LG.

     Inflammation and cancer: extra- and intracellular determinants of tumor-associated macrophages as tumor promoters. Mediators Inflamm. 2017; 2017: 9294018 doi: 10.1155/2017/9294018.

     OpenUrlCrossRef
137. 137.↵
     2. Salmiheimo A,
     3. Mustonen H,
     4. Vainionpää S,
     5. Shen Z,
     6. Kemppainen E,
     7. Puolakkainen P, et al.

     Tumour-associated macrophages activate migration and STAT3 in pancreatic ductal adenocarcinoma cells in co-cultures. Pancreatology. 2017; doi: 10.1016/j.pan.2017.04.013.

     OpenUrlCrossRef
138. 138.↵
     2. Huang J,
     3. Shen FR,
     4. Huang HT,
     5. Ling CH,
     6. Zhang GB.

     Th1high in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC. Oncotarget. 2017; 8: 13116–25. doi: 10.18632/oncotarget.14471.

     OpenUrlCrossRef
139. 139.↵
     2. Meng J,
     3. Zhang XT,
     4. Liu XL,
     5. Fan L,
     6. Li C,
     7. Sun Y, et al.

     WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways. Cell Signal. 2016; 28: 1673–82.

     OpenUrl
140. 140.
     2. Abdelhamed S,
     3. Ogura K,
     4. Yokoyama S,
     5. Saiki I,
     6. Hayakawa Y.

     AKT-STAT3 pathway as a downstream target of EGFR signaling to regulate PD-L1 expression on NSCLC cells. J Cancer. 2016; 7: 1579–86.

     OpenUrlCrossRef
141. 141.
     2. Zhang N,
     3. Zeng YY,
     4. Du WW,
     5. Zhu JJ,
     6. Shen D,
     7. Liu ZY, et al.

     The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol. 2016; 49: 1360–8.

     OpenUrlCrossRefPubMed
142. 142.↵
     2. Sumimoto H,
     3. Takano A,
     4. Teramoto K,
     5. Daigo Y.

     RAS-mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers. PLoS One. 2016; 11: e0166626
143. 143.↵
     2. Huang Q,
     3. Han JL,
     4. Fan JS,
     5. Duan LM,
     6. Guo MF,
     7. Lv ZL, et al.

     IL-17 induces EMT via Stat3 in lung adenocarcinoma. Am J Cancer Res. 2016; 6: 440–51.

     OpenUrlPubMed
144. 144.↵
     2. Dong WL,
     3. Sun SW,
     4. Cao XC,
     5. Cui YH,
     6. Chen A,
     7. Li X, et al.

     Exposure to TNF-α combined with TGF-β induces carcinogenesis in vitro via NF-κB/Twist axis. Oncol Rep. 2017; 37: 1873–82.

     OpenUrl
145. 145.↵
     2. Wamsley JJ,
     3. Kumar M,
     4. Allison DF,
     5. Clift SH,
     6. Holzknecht CM,
     7. Szymura SJ, et al.

     Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer. Cancer Res. 2015; 75: 426–35.

     OpenUrlAbstract/FREE Full Text
146. 146.↵
     2. Keglowich L,
     3. Roth M,
     4. Philippova M,
     5. Resink T,
     6. Tjin G,
     7. Oliver B, et al.

     Bronchial smooth muscle cells of asthmatics promote angiogenesis through elevated secretion of CXC-chemokines (ENA-78, GRO-α, and IL-8). PLoS One. 2013; 8: e81494
147. 147.↵
     2. Phillips KLE,
     3. Cullen K,
     4. Chiverton N,
     5. Michael ALR,
     6. Cole AA,
     7. Breakwell LM, et al.

     Potential roles of cytokines and chemokines in human intervertebral disc degeneration: interleukin-1 is a master regulator of catabolic processes. Osteoarthritis Cartilage. 2015; 23: 1165–77.

     OpenUrlCrossRef
148. 148.↵
     2. Singha B,
     3. Gatla HR,
     4. Manna S,
     5. Chang TP,
     6. Sanacora S,
     7. Poltoratsky V, et al.

     Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem. 2014; 289: 2687–700.

     OpenUrlAbstract/FREE Full Text
149. 149.
     2. Zhang L,
     3. Shao LG,
     4. Creighton CJ,
     5. Zhang YQ,
     6. Xin L,
     7. Ittmann M, et al.

     Function of phosphorylation of NF-κB p65 ser536 in prostate cancer oncogenesis. Oncotarget. 2015; 6: 6281–94.

     OpenUrlCrossRefPubMed
150. 150.
     2. Mizutani T,
     3. Ishizaka A,
     4. Furuichi Y.

     The werner protein acts as a coactivator of nuclear factor κB (NF-κB) on HIV-1 and interleukin-8 (IL-8) promoters. J Biol Chem. 2015; 290: 18391–9.

     OpenUrlAbstract/FREE Full Text
151. 151.↵
     2. Alam M,
     3. Rajabi H,
     4. Ahmad R,
     5. Jin CN,
     6. Kufe D.

     Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget. 2014; 5: 2622–34.

     OpenUrlPubMed
152. 152.↵
     2. Jiang L,
     3. Yin M,
     4. Wei XX,
     5. Liu JX,
     6. Wang XH,
     7. Niu C, et al.

     Bach1 represses Wnt/β-catenin signaling and angiogenesis. Circ Res. 2015; 117: 364–75.

     OpenUrlAbstract/FREE Full Text
153. 153.↵
     2. Jang J,
     3. Ha JH,
     4. Chung SI,
     5. Yoon Y.

     B-catenin regulates NF-κB activity and inflammatory cytokine expression in bronchial epithelial cells treated with lipopolysaccharide. Int J Mol Med. 2014; 34: 632–8.

     OpenUrlCrossRef
154. 154.↵
     2. Kim KN,
     3. Ko SC,
     4. Ye BR,
     5. Kim MS,
     6. Kim J,
     7. Ko EY, et al.

     5-Bromo-2-hydroxy-4-methyl-benzaldehyde inhibited LPS-induced production of pro-inflammatory mediators through the inactivation of ERK, p38, and NF-κB pathways in RAW 264.7 macrophages. Chem Biol Interact. 2016; 258: 108–14.

     OpenUrl
155. 155.↵
     2. Rahman MM,
     3. Alkhouri H,
     4. Tang F,
     5. Che WC,
     6. Ge Q,
     7. Ammit AJ.

     Sphingosine 1-phosphate induces neutrophil chemoattractant IL-8: repression by steroids. PLoS One. 2014; 9: e92466
156. 156.↵
     2. Hsieh YY,
     3. Shen CH,
     4. Huang WS,
     5. Chin CC,
     6. Kuo YH,
     7. Hsieh MC, et al.

     Resistin-induced stromal cell-derived factor-1 expression through Toll-like receptor 4 and activation of p38 MAPK/ NFκB signaling pathway in gastric cancer cells. J Biomed Sci. 2014; 21: 59

     OpenUrlCrossRefPubMed
157. 157.↵
     2. Clifford RL,
     3. Patel JK,
     4. John AE,
     5. Tatler AL,
     6. Mazengarb L,
     7. Brightling CE, et al.

     CXCL8 histone H3 acetylation is dysfunctional in airway smooth muscle in asthma: regulation by BET. Am J Physiol Lung Cell Mol Physiol. 2015; 308: L962–72.

     OpenUrlCrossRefPubMed
158. 158.↵
     2. Wadhwa E,
     3. Nicolaides T.

     Bromodomain inhibitor review: bromodomain and extra-terminal family protein inhibitors as a potential new therapy in central nervous system tumors. Cureus. 2016; 8: e620
159. 159.↵
     2. Shi J,
     3. Whyte WA,
     4. Zepeda-Mendoza CJ,
     5. Milazzo JP,
     6. Shen C,
     7. Roe JS, et al.

     Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 2013; 27: 2648–62.

     OpenUrlAbstract/FREE Full Text
160. 160.↵
     2. Perry MM,
     3. Durham AL,
     4. Austin PJ,
     5. Adcock IM,
     6. Chung KF.

     BET bromodomains regulate transforming growth factor-β-induced proliferation and cytokine release in asthmatic airway smooth muscle. J Biol Chem. 2015; 290: 9111–21.

     OpenUrlAbstract/FREE Full Text
161. 161.↵
     2. Sionov RV,
     3. Vlahopoulos SA,
     4. Granot Z.

     Regulation of Bim in health and disease. Oncotarget. 2015; 6: 23058–134.

     OpenUrlCrossRefPubMed
162. 162.↵
     2. Mehla K,
     3. Singh PK.

     MUC1: a novel metabolic master regulator. Biochim Biophys Acta. 2014; 1845: 126–35.

     OpenUrl
163. 163.↵
     2. Bouillez A,
     3. Rajabi H,
     4. Pitroda S,
     5. Jin CN,
     6. Alam M,
     7. Kharbanda A, et al.

     Inhibition of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung adenocarcinomas. Cancer Res. 2016; 76: 1538–48.

     OpenUrlAbstract/FREE Full Text
164. 164.↵
     2. Tagde A,
     3. Rajabi H,
     4. Stroopinsky D,
     5. Gali R,
     6. Alam M,
     7. Bouillez A, et al.

     MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016; 7: 38974–87.

     OpenUrl
165. 165.↵
     2. Kato K,
     3. Uchino R,
     4. Lillehoj EP,
     5. Knox K,
     6. Lin Y,
     7. Kim KC.

     Membrane-tethered MUC1 mucin counter-regulates the phagocytic activity of macrophages. Am J Respir Cell Mol Biol. 2016; 54: 515–23.

     OpenUrl
166. 166.↵
     2. Barham W,
     3. Chen LY,
     4. Tikhomirov O,
     5. Onishko H,
     6. Gleaves L,
     7. Stricker TP, et al.

     Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ. BMC Cancer. 2015; 15: 647

     OpenUrl
167. 167.↵
     2. Liu X,
     3. Caffrey TC,
     4. Steele MM,
     5. Mohr A,
     6. Singh PK,
     7. Radhakrishnan P, et al.

     MUC1 regulates cyclin D1 gene expression through p120 catenin and β-catenin. Oncogenesis. 2014; 3: e107
168. 168.↵
     2. Li Y,
     3. Yi HY,
     4. Yao YX,
     5. Liao XD,
     6. Xie YQ,
     7. Yang J, et al.

     The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin. PLoS One. 2011; 6: e19102
169. 169.↵
     2. Kufe DW.

     MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013; 32: 1073–81.

     OpenUrlCrossRefPubMedWeb of Science
170. 170.↵
     2. Nishida A,
     3. Lau CW,
     4. Zhang M,
     5. Andoh A,
     6. Shi HN,
     7. Mizoguchi E, et al.

     The membrane-bound mucin Muc1 regulates T helper 17-cell responses and colitis in mice. Gastroenterology. 2012; 142: 865–74.

     OpenUrlCrossRefPubMedWeb of Science
171. 171.↵
     2. Gaemers IC,
     3. Vos HL,
     4. Volders HH,
     5. van der Valk SW,
     6. Hilkens J.

     A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem. 2001; 276: 6191–9.

     OpenUrlAbstract/FREE Full Text
172. 172.↵
     2. Banerjee S,
     3. Mujumdar N,
     4. Dudeja V,
     5. Mackenzie T,
     6. Krosch TK,
     7. Sangwan V, et al.

     MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization. PLoS One. 2012; 7: e43020
173. 173.↵
     2. Vlahopoulos S,
     3. Critselis E,
     4. Voutsas IF,
     5. Perez SA,
     6. Moschovi M,
     7. Baxevanis CN, et al.

     New use for old drugs? Prospective targets of chloroquines in cancer therapy Curr Drug Targets. 2014; 15: 843–51.

     OpenUrl
174. 174.↵
     2. Huang WC,
     3. Chan ML,
     4. Chen MJ,
     5. Tsai TH,
     6. Chen YJ.

     Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. Oncotarget. 2016; 7: 39363–75.

     OpenUrl
175. 175.↵
     2. Wu S,
     3. Ge YL,
     4. Huang LQ,
     5. Liu HY,
     6. Xue Y,
     7. Zhao Y.

     BRG1, the ATPase subunit of SWI/SNF chromatin remodeling complex, interacts with HDAC2 to modulate telomerase expression in human cancer cells. Cell Cycle. 2014; 13: 2869–78.

     OpenUrlCrossRefPubMed
176. 176.↵
     2. Zhou Z,
     3. Su Y,
     4. Fa X.

     Restoration of BRG1 inhibits proliferation and metastasis of lung cancer by regulating tumor suppressor miR-148b. OncoTargets Ther. 2015; 8: 3603–12.

     OpenUrl
177. 177.↵
     2. Obeid S,
     3. Hebbard L.

     Role of adiponectin and its receptors in cancer. Cancer Biol Med. 2012; 9: 213–20.

     OpenUrlAbstract/FREE Full Text
178. 178.↵
     2. Wu D,
     3. Wu P,
     4. Zhao L,
     5. Huang L,
     6. Zhang Z,
     7. Zhao S, et al.

     NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis. Medicine. 2015; 94: e1687
179. 179.↵
     2. Liao C,
     3. Yu ZB,
     4. Guo W,
     5. Liu QY,
     6. Wu YN,
     7. Li YF, et al.

     Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomark. 2014; 14: 469–81.

     OpenUrlPubMed
180. 180.↵
     2. Xu YH,
     3. Lu S.

     A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur J Surg Oncol. 2014; 40: 311–7.

     OpenUrlCrossRefPubMed
181. 181.↵
     2. Marrugal Á,
     3. Ojeda L,
     4. Paz-Ares L,
     5. Molina-Pinelo S,
     6. Ferrer I.

     Proteomic-based approaches for the study of cytokines in lung cancer. Dis Markers. 2016; 2016: 2138627

     OpenUrl
182. 182.↵
     2. Fang YY,
     3. Bi FF,
     4. Zhou YM,
     5. Sun WP,
     6. Li CY,
     7. Liu Q, et al.

     Nicotinamide adenine dinucleotide (NAD) may affect DNA methyltransferase 1 through regulation of BRCA1 in ovarian cancer. Am J Cancer Res. 2015; 5: 1199–206.

     OpenUrl
183. 183.↵
     2. Buckley NE,
     3. Haddock P,
     4. De Matos Simoes R,
     5. Parkes E,
     6. Irwin G,
     7. Emmert-Streib F, et al.

     A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer. Oncotarget. 2016; 7: 19884–96.

     OpenUrl